Magnetic Resonance Imaging trials for Pancreatic cancer

All Magnetic Resonance Imaging trials · All Pancreatic cancer trials

Phase breakdown

Recruiting trials studying Magnetic Resonance Imaging for Pancreatic cancer

• A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
  NCT06906562 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 109 locations
• AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
  NCT07619313 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
  NCT04858334 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 454 locations
• Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE
  NCT06849063 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
  NCT07226856 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
  NCT05733000 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
  NCT04239573 · Phase: Not specified · Ages: 50 Years to 75 Years · Sex: All (male and female) · 429 locations
• Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms
  NCT07529483 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study
  NCT05961982 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
  NCT06454383 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
  NCT06423326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
  NCT04858009 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• MRE for Diagnosis of Pancreatic Masses
  NCT06526442 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
  NCT07089940 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
  NCT07214298 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
  NCT06122896 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)
  NCT05191940 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
  NCT06016855 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
  NCT06958328 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 322 locations
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
  NCT05687123 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
  NCT04172532 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 44 locations

Common questions

How many trials study Magnetic Resonance Imaging for Pancreatic cancer?

22 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.